FDA clears Zygolide as first generic pergolide for equine PPID

Dechra has launched Zygolide, a newly FDA-approved pergolide tablet for horses with pituitary pars intermedia dysfunction, making it the first generic bioequivalent alternative to Prascend for control of clinical signs associated with equine Cushing’s disease. The FDA announced the approval on January 9, 2026, after Dechra said on January 5 that the product would be available through veterinarians that month. (fda.gov)

The move lands in a well-established but clinically important category. Prascend, the original branded pergolide product, was first approved in 2011, and pergolide has remained the main medical therapy for PPID, a common endocrine disorder in aging horses. Recent reviews and veterinary references continue to describe PPID as affecting roughly 20% to 25% of horses older than 15, with prevalence rising further in older age groups, underscoring why access and adherence remain persistent concerns in equine practice. (fda.gov)

Zygolide contains 1 mg pergolide tablets and carries the same core indication as the reference drug. FDA said the agency determined the product is bioequivalent to Prascend. According to the label, the starting dose is 2 mcg/kg orally once daily, with titration based on clinical response and endocrine testing, up to a maximum of 4 mcg/kg daily. In the effectiveness data cited in the prescribing information, 86 of 113 evaluable horses, or 76.1%, were considered treatment successes at Day 180, while 41.6% required a dose increase at Day 90. (fda.gov)

Dechra’s differentiation strategy is practical rather than mechanistic. The company says Zygolide’s tablet has 360-degree scoring, a manageable size and shape, peppermint flavoring, and packaging intended to protect stability and support accurate dosing. The company also says the generic positioning could reduce treatment costs, particularly for horses needing higher doses, although it did not publicly disclose broad list pricing in the press release. The source material provided to The Herd similarly emphasizes administration, daily-care practicality, and cost-effectiveness. (dechra-us.com)

The only direct expert commentary located in primary-source materials came from Dechra. Greg Schmid, DVM, the company’s equine medical affairs lead, said the approval brings “a high-quality, cost-effective option” that could make PPID management more accessible. Independent expert reaction specific to the Zygolide launch was limited in readily available primary reporting, but the broader literature is consistent on the clinical challenge: PPID is chronic, treatment is long term, and outcomes depend heavily on dose titration, monitoring, and day-to-day administration success. (dechra-us.com)

Why it matters: For veterinary professionals, a second FDA-approved pergolide option could improve flexibility in managing one of the most common diseases of senior horses. That matters not just at initiation, but over months and years of follow-up, when appetite changes, dose adjustments, laminitis risk, endocrine retesting, and pet parent adherence all shape real-world outcomes. A lower-cost generic may help some clients stay on therapy, while the scored tablet format may make individualized dosing simpler in horses that don’t fit neatly into whole-tablet increments. (dechra-us.com)

There are still practical cautions. The label warns against crushing tablets because pergolide exposure can cause human adverse effects, including dizziness and low blood pressure, and pregnant or lactating women should wear gloves when administering the drug. Inappetence is the most common adverse event in the field study, and the product has not been evaluated in breeding, pregnant, or lactating horses. Those details may shape how veterinarians counsel barn staff and pet parents, especially when splitting tablets or troubleshooting early intolerance. (fda.gov)

What to watch: The next signal for the market will be whether Zygolide meaningfully changes prescribing patterns, pharmacy uptake, or adherence in PPID cases during 2026, particularly in senior horses requiring long-term dose titration and regular endocrine monitoring. (dechra-us.com)